Four‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the four‑year follow‑up data from the First-in-Human BIOMAG™-I Clinical Study (NCT04157153)* presented at the EuroPCR conference in Paris, France by Prof. Jan Torzewski (Klinikverbund Allgäu, Germany). Conducted exclusively across European centers and enrolling 116 patients, the study continues to demonstrate a favorable long‑term safety profile1, with no new cardia.

Business Wire • Jun 9, 2026

TFX Stock Setup: Valuation, Leverage, and a Neutral Zacks Rank

Teleflex's portfolio reset is pressuring results, but a cheaper valuation and divestiture proceeds could reshape its outlook over the next 6-12 months.

Zacks Investment Research • Jun 1, 2026

Teleflex Incorporated Announces Private Offering of $500 Million of Senior Notes Due 2032

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (“Teleflex”) announced today the commencement of a private offering of $500.0 million aggregate principal amount of senior notes due 2032 (the “Notes”), subject to market and other conditions. The interest rate and other terms of the Notes will be determined at pricing. The Notes will be guaranteed by each of Teleflex's existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under its credit agree.

Business Wire • Jun 1, 2026

Teleflex Incorporated Announces Pricing of $500 Million Senior Notes Offering

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (“Teleflex”) announced today that it priced its private offering of $500.0 million aggregate principal amount of 5.875% senior notes due 2032 (the “Notes”) at an issue price of 100.000%. The sale of the Notes is expected to close on June 15, 2026, subject to customary closing conditions. The Notes will be guaranteed by each of Teleflex's existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor unde.

Business Wire • Jun 1, 2026

Teleflex Divestitures: What Investors Should Watch in 2026

TFX targets $2.03B in divestiture proceeds; FTC review, tariffs and remediation costs put 2026 timing, margins and leverage in play.

Zacks Investment Research • May 29, 2026

Teleflex Showcases New Clinical Data at Leading Urological Congresses Highlighting Patient Experience Advantages of the UroLift™ System and Long-Term Toxicity Reduction with Barrigel™ Rectal Spacer

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the Interventional Urology Business Unit has released new clinical data across two major urological congresses, reinforcing the value of the UroLift™ System and Barrigel™ rectal spacer in improving patient-centered outcomes across benign prostatic hyperplasia (BPH) and prostate cancer care. Teleflex Interventional Urology innovations help urologists treat medical ne.

Business Wire • May 21, 2026

Teleflex Announces Quarterly Dividend

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 30, 2026, to shareholders of record at the close of business on May 25, 2026. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the.

Business Wire • May 15, 2026

TFX Stock Down Post Q1 Earnings & Revenue Beat, Margins Crash

Teleflex beats Q1 earnings and revenue estimates, but steep margin declines and a 52.1% drop in operating profit pressure shares.

Zacks Investment Research • May 13, 2026

Teleflex Incorporated (TFX) Q1 2026 Earnings Call Transcript

Teleflex Incorporated (TFX) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 7, 2026

Teleflex Reports First Quarter Financial Results and Full Year 2026 Outlook

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 31, 2026. First quarter 2026 continuing operations financial summary1 Revenue from continuing operations of $548.3 million, up 32.3% compared to the prior year period, and up 5.1% on a pro forma adjusted constant currency basis1,2 GAAP diluted EPS from continuing operations of $(0.11), compared to $1.14 in the prior year period Adjusted diluted EPS f.

Business Wire • May 7, 2026